Medscape is available in 5 Language Editions – Choose your Edition here.


Prenatal Diagnosis for Congenital Malformations and Genetic Disorders

  • Author: Teresa Marino, MD; Chief Editor: Ronald M Ramus, MD  more...
Updated: Jan 15, 2015


Congenital abnormalities account for 20-25% of perinatal deaths. Many genetic disorders can be detected early in pregnancy using various noninvasive and invasive techniques. These techniques are outlined below.

Noninvasive techniques

Fetal visualization includes the following noninvasive modalities:

  • Ultrasound
  • Fetal echocardiography
  • Magnetic resonance imaging (MRI)
  • Radiography

Screening for neural tube defects (NTDs) involves measuring maternal serum alpha-fetoprotein (MSAFP).

Screening for fetal Down syndrome includes the following:

  • Measuring MSAFP
  • Measuring maternal unconjugated estriol
  • Measuring maternal serum beta-human chorionic gonadotropin (HCG)
  • Measuring inhibin

Other noninvasive techniques include the following:

  • Separation of fetal cells from the mother's blood
  • Assessment of fetal-specific DNA methylation ratio [1]

Invasive techniques

Fetal visualization techniques that are invasive include the following:

  • Embryoscopy
  • Fetoscopy

Invasive fetal tissue sampling techniques include the following:

  • Amniocentesis
  • Chorionic villus sampling (CVS)
  • Percutaneous umbilical blood sampling (PUBS)
  • Percutaneous skin biopsy
  • Other organ biopsies, including muscle and liver biopsy

Preimplantation biopsy of blastocysts obtained by in vitro fertilization is an invasive technique.

Cytogenetic investigations that are invasive include the following:

  • Detection of chromosomal aberrations
  • Fluorescent in situ hybridization

Invasive molecular genetic techniques include the following:

  • Linkage analysis using microsatellite markers
  • Restriction fragment length polymorphisms (RFLPs)
  • Single nucleotide polymorphisms (SNPs) - DNA chip, dynamic allele-specific hybridization (DASH)

Noninvasive Techniques

Fetal visualization - Ultrasound

Ultrasound is a noninvasive procedure for imaging fetal anatomy. It is harmless to both the fetus and the mother. Ultrasound can evaluate gestational age, as well as identify twins; fetal position; placental location; fetal growth, development, and movement; and any structural birth defects. It also can assess amniotic fluid volume.

Many fetal organ systems and anatomical lesions, including some genitourinary, gastrointestinal, skeletal, and central nervous system abnormalities and congenital cardiopathies, can be visualized by ultrasound between 16-20 weeks' gestation. Using ultrasound, Romain et al[2] carried out prenatal detection of congenital cataract in an unborn fetus with trisomy 21. Aslan et al[3] carried out prenatal diagnosis of Neu-Laxova syndrome at 38 weeks' gestation. Ultrasound also is used to guide invasive sampling, such as amniocentesis, CVS, cordocentesis, and various fetal biopsies.

Bernard et al found that spina bifida may be detected early in pregnancy with biparietal diameter (BPD) on ultrasound. BPD is lower in spina bifida babies. Half of the deformities could be detected by this modality.[4]

Fetal visualization - Fetal echocardiography

Fetal echocardiography can be performed at 15 weeks' gestation and beyond. When this technique is used with duplex or color flow Doppler, it can identify a number of major structural cardiac defects and rhythm disturbances.[5] By fetal echocardiography, Saygili et al[6] diagnosed absent pulmonary valve syndrome in a male infant prenatally at 22 weeks' gestation. Fetal echocardiography is recommended in cases where cardiac defects are suspected, including the following:

  • Identification of an extracardiac malformation on routine ultrasound
  • Abnormality of another major organ system
  • Suspected genetic disease or fetal chromosome abnormality associated with heart defects
  • Exposure to potentially teratogenic agents
  • Family history of congenital heart defects, particularly in a parent or sibling
  • Maternal diseases, such as diabetes or phenylketonuria associated with fetal structural heart defects, in particular heart blocks, such as lupus or other immune disorders
  • Alcohol or drug consumption by mother during pregnancy
  • Maternal rubella infection during pregnancy

Fetal visualization - MRI

MRI is a fetal imaging technique that uses powerful magnets and radio waves to construct images of the body, but, because of fetal movements, its application has been limited. Glenn et al reported a prenatal diagnosis of polymicrogyria using MRI as an imaging technique.[7]

Fetal visualization - Radiography

The fetal skeleton can be visualized by radiography from 10 weeks' gestation onward. This technique is used for the diagnosis of inherited skeletal dysplasias, particularly osteochondrodysplasia, in the second and third trimesters. Aslan et al[3] carried out prenatal diagnosis of thanatophoric dysplasia at 19 weeks' gestation in an 18-year-old woman. Because of the dangers of radiography to the fetus, this technique rarely is used.

Screening for neural tube defects

Screening for NTDs is recommended if the following are present:

  • Ultrasound findings indicate NTDs.
  • A child with NTDs is already in the family.
  • A family history of NTDs exists, especially a mother with NTDs.
  • The mother has type 1 diabetes mellitus during pregnancy.
  • Maternal exposure to drugs, such as valproic acid, is associated with NTDs.
  • Elevated level of MSAFP is present.

Measuring maternal serum alpha-fetoprotein

The developing fetus has 2 major blood proteins, albumin and alpha-fetoprotein (AFP), while adults have only albumin in their blood. The MSAFP level can be used to determine the AFP levels from the fetus. AFP is produced by the yolk sac and later by the liver; it enters the amniotic fluid and then the maternal serum via fetal urine.

In the condition of an open NTD (eg, anencephaly, spina bifida) and abdominal wall defects in the fetus, AFP diffuses rapidly from exposed fetal tissues into amniotic fluid, and the MSAFP level rises. However, the MSAFP levels also increase with gestational age, gestational diabetes, twins, pregnancies complicated by bleeding, and in association with intrauterine growth retardation.

The MSAFP test has the greatest sensitivity between 16-18 weeks' gestation, but it also can be performed between 15-22 weeks' gestation. A combination of the MSAFP test and ultrasonography detects almost all cases of anencephaly and most cases of spina bifida. Also, a NTD can be distinguished from other fetal defects, such as abdominal wall defects, by the use of an acetylcholinesterase test carried out on amniotic fluid obtained by amniocentesis. If the level of acetylcholinesterase rises along with amniotic fluid AFP, it is suspected as a condition of a NTD.[8]

Screening for fetal Down syndrome - Measuring maternal serum alpha-fetoprotein

In cases where a low level of MSAFP is reported, it indicates the condition of Down syndrome or other chromosomal aneuploidy and failing pregnancies.[9, 10]

Screening for fetal Down syndrome - Measuring maternal unconjugated estriol

The amount of estriol in maternal serum depends upon viable fetus, a properly functioning placenta, and on maternal well-being. Fetal adrenal glands produce dehydroepiandrosterone (DHEA) that gets metabolized to estriol in the placenta. Estriol crosses to the maternal circulation and is excreted either by maternal kidney in urine or by maternal liver in the bile. In the third trimester, the level of estriol gives an indication for the well-being of the fetus. A low level of estriol is an indication of Down syndrome and adrenal hyperplasia with anencephaly.[11, 12] If the estriol level drops to a great level, then it indicates risk to fetus.

Screening for fetal Down syndrome - Measuring maternal serum beta-human chorionic gonadotropin

Following conception and implantation of the developing embryo into the uterus, the trophoblasts produce enough beta-HCG, which is an indication for pregnancy. In the middle to late second trimester, the level of beta-HCG also can be used in conjunction with the MSAFP level to screen for chromosomal abnormalities. An increased beta-HCG level coupled with a decreased MSAFP level suggests Down syndrome.[10, 13] The beta-HCG level also can be quantified in serum from maternal blood, and, if its amount is found to be lower than expected, it indicates abortion or ectopic pregnancy. If the level of HCG is estimated to be considerably high, then it indicates the possibility of trophoblastic diseases. The elevated level of HCG, along with absence of the fetus on ultrasonography, indicates a hydatidiform mole.

Screening for fetal Down syndrome - Measuring maternal inhibin-A levels

The hormone inhibin is secreted by the placenta and the corpus luteum. Inhibin-A can be measured in maternal serum. An increased level of inhibin-A is linked with an increased risk for trisomy 21. A high inhibin-A level may also be associated with a risk for preterm delivery.

Screening for fetal Down syndrome - Cell-free fetal nucleic acids from the placenta

Cell-free fetal DNA and RNA can be extracted from maternal blood around 7 weeks’ gestation, which can be used to screen for Down syndrome, as well as other trisomies (18 and 13), fetal sex, and common sex chromosome aneuploidies (45,X; 47,XXX; 47,XXY; 47,XYY).[14, 15] Sex determination for families with inherited sex-linked diseases, diagnosis of certain single gene disorders, and blood Rhesus factor status (in the case of Rhesus D-negative mothers) can also be performed using cell-free fetal nucleic acids from the placenta.

Screening for fetal Down syndrome - Separation of fetal cells from the mother's blood

Fetal blood cells make access to maternal circulation through the placental villi. These cells can be collected safely from approximately 18 weeks' gestation onward, although by successful procedures, these cells can be collected at 12 weeks' gestation.[16] The fetal cells can be sorted out and analyzed by different techniques.

Fluorescent in situ hybridization (FISH) is one technique that can be used to diagnose aneuploid conditions, such as trisomies and monosomy X. In the condition of fetal infection with such viruses as rubella, cytomegalovirus, and toxoplasmosis, the viral immunoglobulin M (IgM) or DNA also can be identified in fetal blood.[17, 18]

Fetal blood cells can be analyzed for the diagnosis of genetic disorders using molecular genetic techniques by isolating DNA and amplifying it by polymerase chain reaction (PCR). Quantitative PCR (qPCR) may be useful in the rapid prenatal and neonatal diagnosis of Down syndrome by targeting segmental duplications on chromosomes 21 and 11.[19]

Fetal cells separated from a mother's blood have been successfully used in the diagnosis of cystic fibrosis, sickle cell anemia, and thalassemia in a fetus.

Screening for fetal Down syndrome (trisomy 21) – Fetal-specific differentially methylated regions

The free fetal DNA (ffDNA) is present in the maternal circulation during pregnancy. Papageorgiou et al used methylated DNA immunoprecipitation (MeDiP) methodology, which uses an antibody specific for 5-methylcytidine to capture methylated sites and therefore can enrich fetal-specific methylated DNA, in combination with real-time qPCR to determine the fetal chromosome dosage.[1] This is a noninvasive technique that analyzes fetal-specific differentially methylated regions (DMRs). The authors determined the methylation ratio of normal and trisomy 21 cases for each tested fetal-specific DMR present in maternal peripheral blood and could diagnose 14 cases of trisomy 21 and 26 normal cases. This technique can be used in routine practice in diagnostic laboratories for all pregnancies.


Invasive Techniques

Fetal visualization -Embryoscopy

Embryoscopy is performed in the first trimester of pregnancy (up to 12 weeks’ gestation).[20] In this technique, a rigid endoscope is inserted via the cervix in the space between the amnion and the chorion, under sterile conditions and ultrasound guidance, to visualize the embryo for the diagnosis of structural malformations.

Fetal visualization - Fetoscopy

Fetoscopy is performed during the second trimester (after 16 weeks’ gestation). In this technique, a fine-caliber endoscope is inserted into the amniotic cavity through a small maternal abdominal incision, under sterile conditions and ultrasound guidance, for the visualization of the embryo to detect the presence of subtle structural abnormalities. It also is used for fetal blood and tissue sampling. Fetoscopy is associated with a 3-5% risk of miscarriage; therefore, it is superseded by detailed ultrasound scanning.

Fetal tissue sampling - Amniocentesis

Amniocentesis is an invasive, well-established, safe, reliable, and accurate procedure performed at 15-18 weeks. It is performed under ultrasound guidance. A 22-gauge needle is passed through the mother's lower abdomen into the amniotic cavity inside the uterus, and 10-20 mL of amniotic fluid that contains cells from amnion, fetal skin, fetal lungs, and urinary tract epithelium are collected. These cells are grown in culture for chromosomal, biochemical, and molecular biologic analyses. Supernatant amniotic fluid is used for the measurement of substances, such as amniotic fluid AFP, hormones, and enzymes.

The results of cytogenetic and biochemical studies on amniotic cell cultures are more than 90% accurate. In the third trimester of pregnancy, the amniotic fluid can be analyzed for determination of fetal lung maturity. Risks with amniocentesis are rare but include 0.5-1.0% fetal loss and maternal Rh sensitization.

Fetal tissue sampling - Chorionic villus sampling

CVS is performed very early in gestation between 9-12 weeks, ideally at 10 weeks' gestation. A catheter is passed through the cervix or through the abdominal wall into the uterus under ultrasound guidance, and a sample of chorionic villi surrounding the sac is obtained. The villi are dissected from the decidual tissue, and chromosome analysis is carried out on these cells to determine the karyotype of the fetus (see image below).

Prenatal diagnosis for congenital malformations an Prenatal diagnosis for congenital malformations and genetic disorders. Karyotype showing normal male chromosomal constitution (46, XY).

DNA can be extracted from these cells for molecular analysis. DNA analysis of CVS specimens is helpful for early diagnosis of hemoglobinopathies.[21] In addition, tissue culture can be initiated on these cells for further studies.

The major advantage of CVS over amniocentesis is getting quick results and its use in early pregnancy. Abnormalities can be identified at an early stage, and more acceptable decisions about termination of the pregnancy can be taken. Abortion is also much safer at this early stage. A disadvantage of CVS as compared to amniocentesis is a 2-3% risk of causing miscarriage, and, rarely, CVS can result with limb defects in the fetus.[22] Maternal sensitization is possible. A higher rate of maternal cell contamination and confined placental mosaicism with CVS may result in diagnostic ambiguity, leading to the need for additional invasive diagnostic tests.[23]

Fetal tissue sampling - Percutaneous umbilical blood sampling

PUBS is also known as cordocentesis.[18] It is a method for fetal blood sampling and is performed after 16 weeks' gestation. A needle is inserted into the umbilical cord under ultrasound guidance, and fetal blood is collected from the umbilical vein for chromosome analysis and genetic diagnosis. An advantage of PUBS is the rapid rate at which lymphocytes grow, allowing prompt genetic diagnosis.

This technique is also useful for evaluating fetal metabolism and hematologic abnormalities.

Fetal tissue sampling - Percutaneous skin biopsy

To prenatally diagnose a number of serious skin disorders, such as anhidrotic ectodermal dysplasia, epidermolysis bullosa letalis, epidermolysis bullosa dystrophica, hypohidrotic ectodermal dysplasia, oculocutaneous albinism, and genetic forms of ichthyosis, percutaneous fetal skin biopsies are taken under ultrasonic guidance between 17-20 weeks' gestation.

Fetal tissue sampling - Other organ biopsies, including liver and muscle biopsy

Fetal liver biopsy is needed to diagnose an inborn error of metabolism, such as ornithine transcarbamylase deficiency,[24] glucose-6-phosphatase deficiency,[25] glycogen storage disease type IA, nonketotic hyperglycemia,[26] and carbamoyl-phosphate synthetase deficiency.[27] Fetal liver biopsy also is best performed between 17-20 weeks' gestation under ultrasound guidance.

Fetal muscle biopsy is carried out under ultrasound guidance at about 18 weeks' gestation to analyze the muscle fibers histochemically for prenatal diagnosis of Becker-Duchenne muscular dystrophy.[28]

Fetal tissue sampling - Preimplantation biopsy of blastocysts obtained by in vitro fertilization

Techniques are being developed to test cells obtained from biopsy of early cleavage stages or blastocysts of pregnancies conceived through in vitro fertilization.[29] These techniques will be helpful for selective transfer and implantation of those pregnancies into the uterus that are not affected by a specific genetic disorder. This approach will be more acceptable to those couples who oppose abortions.


Cytogenetic Investigations

Detection of chromosomal aberrations

Chromosomal aberrations, such as deletions, duplications, translocations, and inversions diagnosed in affected parents or siblings, can be detected prenatally in a fetus by chromosomal analysis (see image below).

Prenatal diagnosis for congenital malformations an Prenatal diagnosis for congenital malformations and genetic disorders. Karyotype showing trisomy 21 (47, XY, +21) in a male.

This analysis can be undertaken on fetal cells obtained through such techniques as amniocentesis and CVS.

Fluorescent in situ hybridization

FISH uses different fluorescent-labeled probes, which are single-stranded DNA conjugated with fluorescent dyes and are specific to regions of individual chromosomes. These probes hybridize with complementary target DNA sequences[30] in the genome and can detect chromosomal abnormalities, such as trisomies,[31] monosomies, and duplications.

Three types of DNA probes are used in FISH analysis. Whole chromosome probes are specific to a whole chromosome or a chromosome segment and are applied to metaphase spread for the identification of translocations or aneuploidy. Repetitive probes, such as alpha satellite sequences located in the centromeric regions of human chromosomes, are used in the identification of marker chromosomes and aneuploidy. Unique sequence probes are single clones or a series of overlapping clones corresponding to a specific gene or a confined region of a chromosome that do not contain major repetitive sequences and are used for the identification of specific translocation events in cancer[32] and for the detection of submicroscopic deletions.[33]

In 4% of retinoblastoma cases, deletion of chromosome band 13q14 has been reported.[34] Prenatal diagnosis of retinoblastoma cases with deletion of this band on chromosome 13 is feasible using fluorescent-labeled probes for this region. Hybridization of fluorescent DNA probes to interphase nuclei is under investigation as a screening method for aneuploidy.

Microarray comparative genomic hybridization

Recently, array-CGH (microarray comparative genomic hybridization) is considered to be useful in detecting genomic imbalance in the fetus (duplications/deletions).


Molecular Genetic Techniques


Molecular genetic techniques are being used for prenatal diagnosis.[35] These techniques are based upon the fact that DNA complement is generally identical in every cell of the body; therefore, any hereditary defect diagnosed at the DNA level will be present in nucleated cells from that individual. For molecular analysis, DNA is extracted from amniocytes, chorionic villi, or fetal blood cells. Then, it is amplified by PCR and is used for the diagnosis of genetic mutations or deletions within a gene that causes a specific genetic disease. The following molecular biologic techniques can be used for prenatal diagnosis of different diseases.

Linkage analysis by microsatellite markers

Microsatellites are short tandem repeats of 2-6 base pairs that are highly polymorphic and are distributed throughout the genome. This form of polymorphism is inherited in a mendelian codominant manner. For linkage analysis, primers for regions flanking the repeat sequences are designed and used to amplify these microsatellites by PCR, initially for candidate gene regions and on their exclusion for whole genome analysis.

On gel electrophoresis, the genotype of different individuals in the family indicating 2 alleles for each microsatellite marker is established, and haplotypes are constructed with the analyzed markers. Cosegregation of a particular allele of any of these analyzed markers with the disease phenotype, in all the affected but in none of the unaffected individuals, indicates the probability of linkage with that marker at that particular locus, which is confirmed statistically by calculating the lod scores. A lod score value of greater than 3 indicates linkage of that particular marker with the disease locus in that family. In informative families affected with a disease, linkage can be confirmed by lod score and haplotype analysis. Segregation of a particular allele linked with disease phenotype also can be tested in the fetus by haplotype analysis (see image below).

Prenatal diagnosis for congenital malformations an Prenatal diagnosis for congenital malformations and genetic disorders. Segregation of haplotypes for 10 markers (M1-M10) in a family. Diseased haplotype, as indicated by red bars, is shared by all of the affected individuals (filled circles and squares) and by none of the unaffected individuals (unfilled circles and squares).

Carter et al[36] identified an intragenic polymorphic marker linked with human CP49 gene (that codes for intermediate filament protein in lens fiber cells) on chromosome 3 at band 3q21-22 for the genetic linkage analysis of autosomal dominant congenital cataract. Toudjarska et al[37] demonstrated molecular diagnosis of Marfan syndrome by linkage analysis.

Restriction fragment length polymorphism

In the human genome, variations are common and reportedly occur approximately once every 200 base pairs. These single base pair differences in DNA nucleotide sequences are inherited in a mendelian codominant manner. Restriction endonucleases are the enzymes that recognize and cut DNA within a specific base sequence recognition site. If a difference occurs in the DNA sequence within the recognition sequence of a restriction enzyme, it results in fragments of different size by that restriction enzyme. This difference is recognized by the altered mobility of the restriction fragments on gel electrophoresis, which is known as RFLP (see image below). This technique is used to detect deletions within the gene and DNA polymorphisms and to identify mutant genes and mutations at hot spots.

Prenatal diagnosis for congenital malformations an Prenatal diagnosis for congenital malformations and genetic disorders. Pedigree (A) with RFLP analysis (B) with restriction enzyme BfaI. Due to sequence alteration, on restriction analysis affected individuals (4, 10, 14, 21) show 2 bands, whereas unaffected individuals (1, 2, 3, 9, 22) have only 1 undigested fragment.

Churchill et al[38] performed prenatal diagnosis in a familial case of aniridia by extracting DNA from cultured fibroblasts obtained through amniocentesis, RFLP with restriction enzyme Ava1, and electrophoresis by single-strand confirmation polymorphism to screen the PAX6 gene.

Single nucleotide polymorphisms

SNPs are single base differences in the genome of an individual, which occur about every 1000 bases. Each SNP has 2 alleles; they can be used for linkage analysis to carry out fine mapping of regions on the chromosomes and to study mutations in the genes. The advantages of SNPs are their abundant numbers, and they can be typed by oligonucleotide hybridization assay, without gel electrophoresis. Two methods are available for oligonucleotide hybridization assay, DNA chip and DASH.

DNA chip

A DNA chip is a wafer of silicon, usually 2 cm3 or less in area, and carries many different oligonucleotides (short single-stranded DNA molecule less than 50 nucleotides in length synthesized artificially in a test tube) in a high-density array. The DNA to be analyzed is labeled with a fluorescent marker and is pipetted onto the surface of the chip. Hybridization of labeled DNA is detected by examining the chip with a fluorescent microscope. The position where the hybridization signal is emitted indicates which oligonucleotide has hybridized with the test DNA. If there is a single mismatch at a single position within the oligonucleotide, that mismatch does not form a base pair, and hybridization does not occur. In this way, oligonucleotide hybridization discriminates between the 2 alleles of a SNP.

Dynamic allele-specific hybridization

In this technique, hybridization takes place in solution, in 1 of the 96 well microtiter tray. Hybridization is detected by a fluorescent marker that binds only to double-stranded DNA and emits a signal on hybridization. Initially, hybridization is carried out under conditions that allow mismatched hybrids to form, and, at this stage, oligonucleotides and the test DNA hybridize regardless of which SNP allele is contained by the DNA. By raising the temperature, the mismatched hybrids, which are less stable as compared to complete hybrids, break down. Detecting which allele is present in the test DNA can be determined from the temperature at which the hybridization-dependent fluorescent signal disappears.

Currently, SNPs are used for the molecular genetic analysis of many eye disorders, such as congenital cataract, myopia, Marfan syndrome, and glaucoma.


Prerequisites of Prenatal Diagnosis

Prenatal diagnosis is recommended in the following cases:

  • The pregnant woman is 35 years or older at the time of delivery.
  • She or her parents have had a previous child with a chromosomal abnormality.
  • She has a history of recurrent abortions, or her husband's previous wife experienced several miscarriages.
  • A history of parental consanguinity is present.
  • The couple is known to be carriers of a chromosomal translocation.
  • The pregnant woman is affected with type 1 diabetes mellitus, epilepsy, or myotonic dystrophy.
  • She is exposed to viral infections, such as rubella or cytomegalovirus.
  • The mother is exposed to excessive medication or to environmental hazards.
  • In her or her spouse's family, a history of Down syndrome or some other chromosomal abnormality is present.
  • A history of single gene disorder is present in her or her spouse's family.
  • Her male relatives have Duchenne muscular dystrophy or severe hemophilia.
  • She is suspected of having some other harmful gene on her X chromosomes.
  • The fetus is diagnosed in utero to have some hereditary error of metabolism.
  • The fetus is detected to be at increased risk for a NTD.

Benefits of Prenatal Diagnosis

An offer of prenatal screening provides prospective mothers the option of choosing or declining to receive genetic information pertinent to their personal situation prior to conception.[39]

After conception, prenatal diagnosis provides various benefits. Prenatal diagnosis determines the outcome of pregnancy and identifies possible complications that can arise during birth. It can be helpful in improving the outcome of pregnancy using fetal treatment. Screening can help couples determine whether to continue the pregnancy and prepares couples for the birth of a child with an abnormality.

Contributor Information and Disclosures

Teresa Marino, MD Assistant Professor, Attending Physician, Division of Maternal-Fetal Medicine, Tufts Medical Center

Disclosure: Nothing to disclose.

Chief Editor

Ronald M Ramus, MD Professor of Obstetrics and Gynecology, Director, Division of Maternal-Fetal Medicine, Virginia Commonwealth University School of Medicine

Ronald M Ramus, MD is a member of the following medical societies: American College of Obstetricians and Gynecologists, American Institute of Ultrasound in Medicine, Medical Society of Virginia, Society for Maternal-Fetal Medicine

Disclosure: Nothing to disclose.


Gerhard W Cibis, MD Clinical Professor, Director of Pediatric Ophthalmology Service, Department of Ophthalmology, University of Kansas School of Medicine

Gerhard W Cibis, MD is a member of the following medical societies: American Academy of Ophthalmology, American Association for Pediatric Ophthalmology and Strabismus, and American Ophthalmological Society

Disclosure: Nothing to disclose.

J James Rowsey, MD Former Director of Corneal Services, St Luke's Cataract and Laser Institute

J James Rowsey, MD is a member of the following medical societies: American Academy of Ophthalmology, American Association for the Advancement of Science, American Medical Association, Association for Research in Vision and Ophthalmology, Florida Medical Association, Pan-American Association of Ophthalmology, Sigma Xi, and Southern Medical Association

Disclosure: Nothing to disclose.

Hampton Roy Sr, MD Associate Clinical Professor, Department of Ophthalmology, University of Arkansas for Medical Sciences

Hampton Roy Sr, MD is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, and Pan-American Association of Ophthalmology

Disclosure: Nothing to disclose.

Daljit Singh, MBBS, MS, DSc Professor Emeritis, Department of Ophthalmology, Guru Nanak Dev University, Amritsar, India; Director, Daljit Singh Eye Hospital

Daljit Singh, MBBS, MS, DSc is a member of the following medical societies: All India Ophthalmological Society, American Society of Cataract and Refractive Surgery, Indian Medical Association, International Intraocular Implant Club, and Intraocular Implant and Refractive Society, India

Disclosure: Nothing to disclose.

Jai Rup Singh, PhD First Vice Chancellor, Central University of Punjab, Bathinda, India

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Vanita Vanita, MSc, PhD Reader & Head, Centre for Genetic Disorders, Guru Nanak Dev University, Amritsar, Punjab, India

Disclosure: Nothing to disclose.

  1. Papageorgiou EA, Karagrigoriou A, Tsaliki E, Velissariou V, Carter NP, Patsalis PC. Fetal-specific DNA methylation ratio permits noninvasive prenatal diagnosis of trisomy 21. Nat Med. 2011 Mar 6. [Medline].

  2. Romain M, Awoust J, Dugauquier C, Van Maldergem L. Prenatal ultrasound detection of congenital cataract in trisomy 21. Prenat Diagn. 1999 Aug. 19(8):780-2. [Medline].

  3. Aslan H, Gul A, Polat I, Mutaf C, Agar M, Ceylan Y. Prenatal diagnosis of Neu-Laxova syndrome: a case report. BMC Pregnancy Childbirth. 2002. 2(1):1. [Medline]. [Full Text].

  4. Bernard JP, Cuckle HS, Stirnemann JJ, Salomon LJ, Ville Y. Screening for fetal spina bifida by ultrasound examination in the first trimester of pregnancy using fetal biparietal diameter. Am J Obstet Gynecol. 2012 May 18. [Medline].

  5. Copel JA, Pilu G, Green J, Hobbins JC, Kleinman CS. Fetal echocardiographic screening for congenital heart disease: the importance of the four-chamber view. Am J Obstet Gynecol. 1987 Sep. 157(3):648-55. [Medline].

  6. Saygili A, Tiker F, Bagis T, Barutcu O. Absent pulmonary valve syndrome diagnosed by fetal echocardiography. Turk J Pediatr. 2004 Jan-Mar. 46(1):88-91. [Medline].

  7. Glenn OA, Norton ME, Goldstein RB, Barkovich AJ. Prenatal diagnosis of polymicrogyria by fetal magnetic resonance imaging in monochorionic cotwin death. J Ultrasound Med. 2005 May. 24(5):711-6. [Medline].

  8. Nadel AS, Green JK, Holmes LB, Frigoletto FD Jr, Benacerraf BR. Absence of need for amniocentesis in patients with elevated levels of maternal serum alpha-fetoprotein and normal ultrasonographic examinations. N Engl J Med. 1990 Aug 30. 323(9):557-61. [Medline].

  9. Merkatz IR, Nitowsky HM, Macri JN, Johnson WE. An association between low maternal serum alpha-fetoprotein and fetal chromosomal abnormalities. Am J Obstet Gynecol. 1984 Apr 1. 148(7):886-94. [Medline].

  10. Hsu JJ, Hsieh TT, Hsieh FJ. Down syndrome screening in an Asian population using alpha-fetoprotein and free beta-hCG: a report of the Taiwan Down Syndrome Screening Group. Obstet Gynecol. 1996 Jun. 87(6):943-7. [Medline].

  11. Haddow JE, Palomaki GE, Knight GJ, et al. Prenatal screening for Down's syndrome with use of maternal serum markers. N Engl J Med. 1992 Aug 27. 327(9):588-93. [Medline].

  12. Phillips OP, Elias S, Shulman LP, Andersen RN, Morgan CD, Simpson JL. Maternal serum screening for fetal Down syndrome in women less than 35 years of age using alpha-fetoprotein, hCG, and unconjugated estriol: a prospective 2-year study. Obstet Gynecol. 1992 Sep. 80(3 Pt 1):353-8. [Medline].

  13. Bogart MH, Pandian MR, Jones OW. Abnormal maternal serum chorionic gonadotropin levels in pregnancies with fetal chromosome abnormalities. Prenat Diagn. 1987 Nov. 7(9):623-30. [Medline].

  14. Porreco RP, Garite TJ, Maurel K, et al. Noninvasive prenatal screening for fetal trisomies 21, 18, 13 and the common sex chromosome aneuploidies from maternal blood using massively parallel genomic sequencing of DNA. Am J Obstet Gynecol. 2014 Oct. 211(4):365.e1-12. [Medline].

  15. Lo KK, Boustred C, Chitty LS, Plagnol V. RAPIDR: an analysis package for non-invasive prenatal testing of aneuploidy. Bioinformatics. 2014 Oct 15. 30(20):2965-7. [Medline]. [Full Text].

  16. Orlandi F, Damiani G, Jakil C, Lauricella S, Bertolino O, Maggio A. The risks of early cordocentesis (12-21 weeks): analysis of 500 procedures. Prenat Diagn. 1990 Jul. 10(7):425-8. [Medline].

  17. Daffos F, Forestier F, Grangeot-Keros L, et al. Prenatal diagnosis of congenital rubella. Lancet. 1984 Jul 7. 2(8393):1-3. [Medline].

  18. Daffos F, Capella-Pavlovsky M, Forestier F. Fetal blood sampling during pregnancy with use of a needle guided by ultrasound: a study of 606 consecutive cases. Am J Obstet Gynecol. 1985 Nov 15. 153(6):655-60. [Medline].

  19. Sun L, Fan Z, Weng X, et al. Rapid detection of Down's syndrome using quantitative real-time PCR (qPCR) targeting segmental duplications on chromosomes 21 and 11. Gene. 2014 Dec 1. 552(2):272-6. [Medline].

  20. Cullen MT, Reece EA, Whetham J, Hobbins JC. Embryoscopy: description and utility of a new technique. Am J Obstet Gynecol. 1990 Jan. 162(1):82-6. [Medline].

  21. Galjaard H. Fetal diagnosis of inborn errors of metabolism. Baillieres Clin Obstet Gynaecol. 1987 Sep. 1(3):547-67. [Medline].

  22. Burton BK, Schulz CJ, Burd LI. Limb anomalies associated with chorionic villus sampling. Obstet Gynecol. 1992 May. 79(5 (Pt 1)):726-30. [Medline].

  23. Wang BB, Rubin CH, Williams J 3rd. Mosaicism in chorionic villus sampling: an analysis of incidence and chromosomes involved in 2612 consecutive cases. Prenat Diagn. 1993 Mar. 13(3):179-90. [Medline].

  24. Holzgreve W, Golbus MS. Prenatal diagnosis of ornithine transcarbamylase deficiency utilizing fetal liver biopsy. Am J Hum Genet. 1984 Mar. 36(2):320-8. [Medline].

  25. Golbus MS, Simpson TJ, Koresawa M, Appelman Z, Alpers CE. The prenatal determination of glucose-6-phosphatase activity by fetal liver biopsy. Prenat Diagn. 1988 Jul. 8(6):401-4. [Medline].

  26. Anton-Lamprecht I. Genetically induced abnormalities of epidermal differentiation and ultrastructure in ichthyoses and epidermolyses: pathogenesis, heterogeneity, fetal manifestation, and prenatal diagnosis. J Invest Dermatol. 1983 Jul. 81(1 Suppl):149s-56s. [Medline].

  27. Piceni Sereni L, Bachmann C, Pfister U, Buscaglia M, Nicolini U. Prenatal diagnosis of carbamoyl-phosphate synthetase deficiency by fetal liver biopsy. Prenat Diagn. 1988 May. 8(4):307-9. [Medline].

  28. Simpson JL, Elias S. Fetal skin, liver and muscle sampling. Simpson JL, Elias S, eds. Essentials of Prenatal Diagnosis. Churchill Livingstone Inc; 1993. 77.

  29. Handyside AH, Lesko JG, Tarín JJ, Winston RM, Hughes MR. Birth of a normal girl after in vitro fertilization and preimplantation diagnostic testing for cystic fibrosis. N Engl J Med. 1992 Sep 24. 327(13):905-9. [Medline].

  30. Trask BJ. Fluorescence in situ hybridization: applications in cytogenetics and gene mapping. Trends Genet. 1991 May. 7(5):149-54. [Medline].

  31. Elias S, Price J, Dockter M, et al. First trimester prenatal diagnosis of trisomy 21 in fetal cells from maternal blood. Lancet. 1992 Oct 24. 340(8826):1033. [Medline].

  32. Tkachuk DC, Westbrook CA, Andreeff M, et al. Detection of bcr-abl fusion in chronic myelogeneous leukemia by in situ hybridization. Science. 1990 Oct 26. 250(4980):559-62. [Medline].

  33. Kuwano A, Ledbetter SA, Dobyns WB, Emanuel BS, Ledbetter DH. Detection of deletions and cryptic translocations in Miller-Dieker syndrome by in situ hybridization. Am J Hum Genet. 1991 Oct. 49(4):707-14. [Medline].

  34. Yunis JJ, Ramsay N. Retinoblastoma and subband deletion of chromosome 13. Am J Dis Child. 1978 Feb. 132(2):161-3. [Medline].

  35. Antonarakis SE. Diagnosis of genetic disorders at the DNA level. N Engl J Med. 1989 Jan 19. 320(3):153-63. [Medline].

  36. Carter JM, McLean WH, West S, Quinlan RA. Mapping of the human CP49 gene and identification of an intragenic polymorphic marker to allow genetic linkage analysis in autosomal dominant congenital cataract. Biochem Biophys Res Commun. 2000 Apr 13. 270(2):432-6. [Medline].

  37. Toudjarska I, Kilpatrick MW, Lembessis P, et al. Novel approach to the molecular diagnosis of Marfan syndrome: application to sporadic cases and in prenatal diagnosis. Am J Med Genet. 2001 Apr 1. 99(4):294-302. [Medline].

  38. Churchill AJ, Hanson IM, Markham AF. Prenatal diagnosis of aniridia. Ophthalmology. 2000 Jun. 107(6):1153-6. [Medline].

  39. Schoonen M, van der Zee B, Wildschut H, de Beaufort I, de Wert G, de Koning H, et al. Informing on prenatal screening for Down syndrome prior to conception. An empirical and ethical perspective. Am J Med Genet A. 2012 Feb 2. [Medline].

Prenatal diagnosis for congenital malformations and genetic disorders. Karyotype showing normal male chromosomal constitution (46, XY).
Prenatal diagnosis for congenital malformations and genetic disorders. Karyotype showing trisomy 21 (47, XY, +21) in a male.
Prenatal diagnosis for congenital malformations and genetic disorders. Segregation of haplotypes for 10 markers (M1-M10) in a family. Diseased haplotype, as indicated by red bars, is shared by all of the affected individuals (filled circles and squares) and by none of the unaffected individuals (unfilled circles and squares).
Prenatal diagnosis for congenital malformations and genetic disorders. Pedigree (A) with RFLP analysis (B) with restriction enzyme BfaI. Due to sequence alteration, on restriction analysis affected individuals (4, 10, 14, 21) show 2 bands, whereas unaffected individuals (1, 2, 3, 9, 22) have only 1 undigested fragment.
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.